Transcode Therapeutics

RNAZ on Nasdaq. Market value $22m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 8 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

7 investors own more than 5%; 1 of them is pushing for change.

  • DEFJ, LLC
    at least 83.9%0.0 pts
    (filed with 1 related holder)
    Since 3 August 2026
    What they said

    Item 4 of Schedule 13D is hereby amended by adding the below disclosure following the last paragraph of Item 4: On August 3, 2026, upon obtaining the consent of a majority of the holders of the Preferred Stock, and the approval of the Company's Board of Directors, the Company…

    Read the filing
  • Unleash Immuno Oncolytics, Inc.
    Passive investor
    9.9%
    Since 23 July 2026
  • YA II PN, Ltd.
    Passive investor
    at least 9.9%
    (filed with 7 related holders)
    Since 15 April 2026
  • Elena Rosa Braci
    Passive investor
    6.2%
    Since 23 July 2026
  • Daniel Eduardo Katzman
    Passive investor
    5.2%
    Since 23 July 2026
  • Thomas Joseph Tracy
    Activist
    5.0%
    Since 7 March 2025
    What they said

    The original purpose of the transactions that occasioned this filing was an investment by the Reporting Person in the ordinary course of his business and with neither the purpose nor effect of changing or influencing the control of the Issuer, nor in connection with or as a…

    Read the filing
  • SABBY MANAGEMENT, LLC
    Passive investor
    at least 4.9%−5.0 pts
    (filed with 2 related holders)
    Since 31 December 2025
  • Sold down below 5%
    Since 30 June 2025
  • Sold down below 5%
    Since 30 September 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought or sold on the open market in the last 12 months.

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

2 serious warning signs in Transcode Therapeutics’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 15 Apr 2026, plus the 10-Q filed 16 Nov 2026 and 12 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “Due to the Company’s recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern for one year after the issuance of these consolidated financial statements without additional capital becoming available.”
    Show the full paragraph
    These consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the continuation of operations, realization of assets and liquidation of liabilities in the ordinary course of business. Due to the Company’s recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern for one year after the issuance of these consolidated financial statements without additional capital becoming available. These consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

    From the 10-Q filed 16 November 2026, Part I, Item 1. Financial Statements. Read it in the filing

  • Weak checks on its own accounts

    Serious

    The company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.

    “Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of that date, our disclosure controls and procedures were not effective because of the material weakness in our internal control over financial reporting previously reported in our Annual Report on Form 10-K for the year ended December 31, 2025, which has not been remediated as of September 30, 2026.”
    Show the full paragraph
    Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act Rule 13a–15(f) or 15d-15(f). Our internal control system was designed to provide reasonable assurance to our management and our Board regarding the preparation and fair presentation of published financial statements. All internal control systems, no matter how well designed have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Our management, with the participation of our principal executive officer and principal financial officer, assessed the effectiveness of our internal control over financial reporting as of September 30, 2026. Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of that date, our disclosure controls and procedures were not effective because of the material weakness in our internal control over financial reporting previously reported in our Annual Report on Form 10-K for the year ended December 31, 2025, which has not been remediated as of September 30, 2026. Notwithstanding this material weakness, our management concluded that our consolidated financial statements for the nine months ended September 30, 2026 fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in accordance with U.S. GAAP.

    From the 10-Q filed 16 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.